Literature DB >> 29425647

Predicting tyrosinase inhibition by 3D QSAR pharmacophore models and designing potential tyrosinase inhibitors from Traditional Chinese medicine database.

Hongwei Gao1.   

Abstract

BACKGROUND: Tyrosinase plays a key role in the formation of skin melanin. The excessive accumulation of skin melanin will cause the serious aesthetic problems for human beings. HYPOTHESIS/
PURPOSE: To find the potent tyrosinase inhibitors using computational simulation from TCM Database@Taiwan. STUDY
DESIGN: Inhibitors of tyrosinase have been thought as potential drugs for the decrease of melanin synthesis in the process of pigmentation. To develop new tyrosinase inhibitors, we performed a virtual screening from Traditional Chinese medicine (TCM) and Druglike Databases using the best 3D QSAR pharmacophore model as a 3D search query.
METHODS: A total of 109 compounds were obtained after filtering by Lipinski's rule of five. Finally, 148 compounds (22 from training set, 17 from test set, 109 from TCM and Druglike databases) were selected for further docking studies. De Novo Evolution designed the top 10 candidates from the docking results.
RESULTS: Hypo1 was selected as the best quantitative pharmacophore model, because Hypo1 has characters of the highest cost difference (353.773), the lowest RMS (1.985), the lowest Error (121.440), and the best correlation coefficient (0.933). By the analysis of interaction amino acids in the top 10 hits including two controls, HIS42, HIS60, HIS204, HIS208, ARG209 and VAL218 are identified as the key binding site residues, ARG209 and VAL218 are the critical residues for the inhibitory activity of tyrosinase. This finding is consistent with the results from literatures.
CONCLUSION: De Novo Evolution study suggested Tyrosinase_1*_Evo_4, Tyrosinase_23*_Evo_7, magnolone.cdx_15_Evo_4, compound_2.cdx_2_Evo_2, Compound_B_Evo_5, Compound_C_Evo_9, Compound_D_Evo_6 and malabaricone_C.cdx_3_Evo_10 as the potential tyrosinase inhibitor candidates. De Novo Evolution study also suggested compound_2.cdx_2_Evo_2 as the most potential tyrosinase inhibitor candidate. A total of ten novel leading compounds were identified to have the favorable interaction with tyrosinase by the docking analyses.
Copyright © 2017 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Docking; Inhibitors; Pharmacophore models; TCM; Tyrosinase

Mesh:

Substances:

Year:  2017        PMID: 29425647     DOI: 10.1016/j.phymed.2017.11.012

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  5 in total

Review 1.  A comprehensive review on tyrosinase inhibitors.

Authors:  Samaneh Zolghadri; Asieh Bahrami; Mahmud Tareq Hassan Khan; J Munoz-Munoz; F Garcia-Molina; F Garcia-Canovas; Ali Akbar Saboury
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

2.  Predictive QSAR model confirms flavonoids in Chinese medicine can activate voltage-gated calcium (CaV) channel in osteogenesis.

Authors:  Ki Chan; Henry Chi Ming Leung; James Kit-Hon Tsoi
Journal:  Chin Med       Date:  2020-03-31       Impact factor: 5.455

Review 3.  Melanins as Sustainable Resources for Advanced Biotechnological Applications.

Authors:  Hanaa A Galeb; Emma L Wilkinson; Alison F Stowell; Hungyen Lin; Samuel T Murphy; Pierre L Martin-Hirsch; Richard L Mort; Adam M Taylor; John G Hardy
Journal:  Glob Chall       Date:  2020-11-25

4.  The Identification of Novel Inhibitors of Human Angiotensin-converting Enzyme 2 and Main Protease of Sars-Cov-2: A Combination of in silico Methods for Treatment of COVID-19.

Authors:  Vahid Zarezade; Hamzeh Rezaei; Ghodratollah Shakerinezhad; Arman Safavi; Zahra Nazeri; Ali Veisi; Omid Azadbakht; Mahdi Hatami; Mohamad Sabaghan; Zeinab Shajirat
Journal:  J Mol Struct       Date:  2021-04-06       Impact factor: 3.196

5.  Investigative on the Molecular Mechanism of Licorice Flavonoids Anti-Melanoma by Network Pharmacology, 3D/2D-QSAR, Molecular Docking, and Molecular Dynamics Simulation.

Authors:  Yi Hu; Yufan Wu; CuiPing Jiang; Zhuxian Wang; Chunyan Shen; Zhaoming Zhu; Hui Li; Quanfu Zeng; Yaqi Xue; Yuan Wang; Li Liu; Yankui Yi; Hongxia Zhu; Qiang Liu
Journal:  Front Chem       Date:  2022-03-02       Impact factor: 5.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.